In Brief: American Biogenetic Sciences
This article was originally published in The Gray Sheet
American Biogenetic Sciences: Plans fourth quarter launch of its FiF functional intact fibrinogen test following 510(k) clearance by FDA. FiF is intended to provide a "rapid and direct quantitative measurement of clotable levels of fibrin protein in plasma," ABS says. The clearance covers use of the product "for the testing of conditions in which blood coagulation is involved" such as "disseminated intravascular coagulation, cardiovascular disease and primary fibrinolysis." The FiF test is ABS' second commercial test; the company launched its TpP thrombus precursor protein test earlier this year following FDA clearance in late 1996 ("The Gray Sheet" Nov. 4, 1996, I&W-6)...
You may also be interested in...
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.